Key result
Elevated admission BUN is linked to ~2.1-fold higher 30-day mortality in post-MI cardiogenic shock.
Why the study?
Cardiogenic shock is the leading cause of death in patients with AMI, and the short-term prognostic value of admission blood urea nitrogen in this population needed evaluation.
Does admission blood urea nitrogen (>8.95 mmol/L) predict 30-day all-cause mortality and MACE in patients with cardiogenic shock complicating acute myocardial infarction?
Cohort (n=218)
No
Does admission blood urea nitrogen (>8.95 mmol/L) predict 30-day all-cause mortality and MACE in patients with cardiogenic shock complicating acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
Admission BUN >8.95 mmol/L is an easily accessible independent predictor of 30-day mortality and MACE in patients with cardiogenic shock complicating AMI, outperforming other renal markers and improving risk reclassification when added to standard clinical risk models.
Purpose. Cardiogenic shock (CS) is the leading cause of death in patients with acute myocardial infarction (AMI). Our study aimed to evaluate the short‐term prognostic value of admission blood urea nitrogen (BUN) in patients with CS complicating AMI. Materials and Methods. 218 consecutive patients with CS after AMI were enrolled. The primary endpoint was 30‐day mortality. The association of admission BUN and 30‐day mortality and major adverse cardiovascular event (MACE) was investigated by Cox regression. The integrated discrimination improvement (IDI) and net reclassification improvement (NRI) further examined the predictive value of BUN. Results. During a period of 30‐day follow‐up, 105 deaths occurred. Compared to survivors, nonsurvivors had significantly higher admission BUN (p < 0.001), creatinine (p < 0.001), BUN/creatinine (p = 0.03), and a lower glomerular filtration rate (p < 0.001). The area under the curve (AUC) of the 4 indices for predicting 30‐day mortality was 0.781, 0.734, 0.588, and 0.773, respectively. When compared to traditional markers associated with CS, the AUC for predicting 30‐day mortality of BUN, lactate, and left ventricular ejection fraction were 0.781, 0.776, and 0.701, respectively. The optimal cut‐off value of BUN for predicting 30‐day mortality was 8.95 mmol/L with Youden‐Index analysis. Multivariate Cox analysis indicated BUN >8.95 mmol/L was an important independent predictor for 30‐day mortality (HR 2.08, 95%CI 1.28–3.36, p = 0.003) and 30‐day MACE (HR 1.85, 95%CI 1.29–2.66, p = 0.001). IDI (0.053, p = 0.005) and NRI (0.135, p = 0.010) showed an improvement in the accuracy for mortality prediction of the new model when BUN was included compared with the standard model of predictors in previous scores. Conclusion. An admission BUN >8.95 mmol/L was robustly associated with increased short‐term mortality and MACE in patients with CS after AMI. The prognostic value of BUN was superior to other renal markers and comparable to traditional markers. This easily accessible index might be promising for early risk stratification in CS patients following AMI.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2022) conducted a cohort in Cardiogenic shock complicating acute myocardial infarction (n=218). Admission blood urea nitrogen (BUN) >8.95 mmol/L vs. Admission blood urea nitrogen (BUN) <=8.95 mmol/L was evaluated on 30-day all-cause mortality (HR 2.08, 95% CI 1.28–3.36, p=0.003). Admission BUN >8.95 mmol/L independently predicted higher 30-day mortality in patients with cardiogenic shock after acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: